Xue Nannan, Zhou Runze, Deng Ming, Li Yitong, Hu Yong, Gao Liang, Zhang Yunbo, Song Xiangyu, Liu Junqi, Fan Ruitai
Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 453000, P.R. China.
Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Clinics (Sao Paulo). 2021 Apr 26;76:e2226. doi: 10.6061/clinics/2021/e2226. eCollection 2021.
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China. Intensity-modulated radiation therapy and volume-modulated arc therapy have become the main treatments for esophageal carcinoma; however, side effects caused by radiotherapy greatly impact the quality of life in these patients. This study aimed to explore the impact of serum superoxide dismutase (SOD) levels on the prognosis of patients with ESCC undergoing radiotherapy.
Patients aged between 18 and 80 years with lower-middle ESCC who underwent radiotherapy were eligible for this assessment. Adverse events, responses, treatment outcomes, and overall survival (OS) were assessed. Between 2012 and 2014, 195 patients were enrolled, of which 65 were assigned to the low- and high-SOD groups based on their serum SOD values.
The baseline characteristics were similar between the two groups, except for the T staging. Adverse events in the low-SOD group were significantly higher than those in the high-SOD group (radiation esophagitis, p=0.007; radiation pneumonitis, p=0.032; leukopenia, p=0.023; thrombocytopenia, p=0.037; anemia, p=0.041). There were no significant differences in response, treatment outcomes, or OS.
In conclusion, high serum SOD activity improved post-radiotherapy quality of life but did not impact the prognosis of patients with ESCC. To the best of our knowledge, this study is the first to report that serum SOD activity is associated with radiation-induced toxicity and moderately increased radiotherapeutic response in patients with ESCC undergoing radiotherapy.
食管鳞状细胞癌（ESCC）是中国最常见的恶性肿瘤之一。调强放射治疗和容积调强弧形放疗已成为食管癌的主要治疗方法；然而，放疗引起的副作用极大地影响了这些患者的生活质量。本研究旨在探讨血清超氧化物歧化酶（SOD）水平对接受放疗的ESCC患者预后的影响。
年龄在18至80岁之间、接受放疗的中下段ESCC患者符合本评估标准。评估不良事件、反应、治疗结果和总生存期（OS）。2012年至2014年，共纳入195例患者，其中65例根据血清SOD值分为低SOD组和高SOD组。
除T分期外，两组的基线特征相似。低SOD组的不良事件显著高于高SOD组（放射性食管炎，p = 0.007；放射性肺炎，p = 0.032；白细胞减少，p = 0.023；血小板减少，p = 0.037；贫血，p = 0.041）。在反应、治疗结果或OS方面无显著差异。
总之，高血清SOD活性改善了放疗后的生活质量，但不影响ESCC患者的预后。据我们所知，本研究首次报道血清SOD活性与接受放疗的ESCC患者的放射诱导毒性相关，并适度提高了放射治疗反应。
